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INTRODUCTION
A considerable number of studies have demon-
strated that iron affects glucose metabolism (1-4).
Excessive iron accumulation in patients with hemo-
chromatosis, a disorder caused by iron overloading,
often results in the clinical manifestation of type 2
diabetes, which provides clinical evidence that ex-
cessive iron storage is strongly associated with the
development of type 2 diabetes (3, 5). The mecha-
nism underlying the promoting effect of iron on the
development of diabetes is not well known, however,
some evidence indicates that free radical forma-
tion may play a role in the mechanism by disrupt-
ing insulin action and total body glucose disposal.
Iron is a powerful pro-oxidant, and oxidative stress
increases in the case of glucose intolerance. These
observations suggest the possible mechanisms un-
derlying the role of iron in diabetes (1, 2). In ad-
dition, histopathological and clinical findings in
earlier studies have revealed that selective iron-
deposition-induced damage to the β -cells of the pan-
creatic islets may affect insulin secretion and even-
tually lead to diabetes (6-8). However, immuno-
histochemical evidence of this mechanism is quite
rudimentary. Here, we report an autopsy case of
transfusional iron overload and subsequent diabe-
tes, which was encountered by a review of earlier
charts, in order to verify the above observations.
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CASE REPORT
A 30-year-old man who experienced bleeding and
had developed anemia from the age of 7 was diag-
nosed with aplastic anemia in 1993. The primary dis-
ease had been treated using antithymocyte globulin
(ATG), steroids, immunosuppressants, granulocyte-
colony stimulating factor (G-CSF), and anabolic hor-
mones, and he had undergone frequent transfusions
for the anemia. His serum ferritin levels were ex-
tremely high, -ranging between approximately 3900
ng/ml and 9800 ng/ml-, and he was diagnosed
with secondary hemochromatosis. Deferoxamine
mesylate, an iron-chelating agent, was used to facili-
tate iron removal, but the ferritin-reducing effect
was only temporary. His casual blood glucose lev-
els constantly ranged between 150 mg/dl and 290
mg/dl and his hyperglycemia was treated with diet
alone. The patient died of cerebral hemorrhage and
pulmonary hemorrhage, and an autopsy was per-
formed 6 h after death. The liver was enlarged and
weighed 1780 g, and part of the liver was discolored,
suggesting iron deposition (Fig. 1). Hematoxylin-
eosin (HE) immunohistochemical (Fig. 2a) and
Berlin blue staining (Fig. 2b) of the liver revealed
hemosiderin deposition mainly in the hepatic paren-
chyma and Kupffer cells, and weak hemosiderin
staining was observed in the epithelial cells of the
biliary duct. The pancreatic slice exhibited diffuse
dark-brown staining, a characteristic feature of
hemochromatosis (Fig. 3). Berlin blue staining
(Figs. 4, 5) of the pancreas revealed significant he-
mosiderin deposition, mainly in the acinar tissue,
pancreatic islets, interstitium, and pancreatic ducts.
Hemosiderin deposition was predominantly ob-
served in the peri-insular acini.
Fig. 1. Macropathology of the liver (slice)
Fig. 2. The hemosiderin in the liver was detected as
a. brown granules by HE staining (132)
b. blue granules by Berlin blue staining (132)
The scale bars in Figs. 2 and 4-8 represent 20 μ.
Fig. 3. Macropathology of the pancreas (slice)
Fig. 4. Significant hemosiderin deposition was detected as blue
granules in the acinar tissue and in the islets by Berlin blue
staining (66)
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The tissue sections of pancreas were also double-
stained for glucagon, insulin, proinsulin, and he-
mosiderin. 3-Amino-9-ethylcarbazole (AEC) was
used as the chromogen instead of 3, 3’-diamino-
benzidine tetrahydrochloride (DAB), because the
brown color reaction obtained with DAB is similar
to that of hemosiderin. Immunohistochemical stain-
ing of the patient’s pancreas (Fig. 6a) with rabbit
polyclonal anti-human glucagon antibody (Dako,
USA) yielded a staining pattern for glucagon that
was similar to or the same as that seen in the con-
trol islets of the non iron-overloaded subjects (Fig.
6b), suggesting that the ability of the α -cells to se-
crete glucagon was preserved. In contrast, stain-
ing with guinea pig polyclonal anti-insulin antibody
(Dako) revealed that immunoreactive β -cells were
quite sparse in the patient’s tissues (Fig. 7a), but
were abundant and stained intensely in the control
tissues (Fig. 7b). Similar results were obtained on
staining in the patient’s tissue (Fig. 8a) and the
control tissue (Fig. 8b) with a mouse monoclonal
anti-proinsulin antibody (Abcam, UK). These find-
ings suggest that severe iron deposition in β -cells
may interfere with their function and that the β -
cells may lose their ability to produce insulin as a
result.
DISCUSSION
Our patient developed transfusional secondary
hemochromatosis and hyperglycemia, and immu-
nohistochemical analysis revealed severe dysfunc-
tion of the β -cells of the pancreatic islets. Rahier et
Fig. 5. Hemosiderin deposition in the islet cells (132)
Fig. 6. Immunohistochemical staining for glucagon
a. Islet cells of the patient (66)
b. Islet cells of the control (66)
Fig. 7. Immunohistochemical staining for insulin
a. Islet cells of the patient (66)
b. Islet cells of the control (66)
Fig. 8. Immunohistochemical staining for proinsulin
a. Islet cells of the patient (66)
b. Islet cells of the control (66)
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al. (7) reported 7 diabetic patients with primary or
secondary iron overload and observed a marked
decrease in the number of immunoreactive β -cells
in the 4 insulin-requiring diabetic patients among
them, which could explain their clinical symptom.
A relatively normal number of β -cells was found in
other 2 patients without insulin usage, suggesting
that the degree of glucose intolerance was related
to functional β -cell deficiency. The number of im-
munoreactive β -cells in our own case was extremely
low and the cells stained weakly, suggesting dys-
function of the β -cells due to [1] a decrease in their
number, although we did not confirm this possibil-
ity by morphometry, [2] failure to synthesize and
secrete adequate amounts of immunoreactive insu-
lin, or [3] both of these. In comparison with the con-
trol, α -cells in our patient showed normal to slightly
less than normal staining. All these findings confirm
the findings of the earlier studies (7, 8), including
clinical findings of excessive glucagon secretion and
deficient insulin response to arginine administration
(6), and support the scientific data indicating selec-
tive iron deposition in the β -cells in patients with
hemochromatosis.
In the earlier report, immunohistochemical and
electron microscopic analysis revealed that the iron
deposits were restricted to β -cells and were asso-
ciated with progressive loss of the endocrine gran-
ules in the β -cell (7), but the mechanism how this
exclusive iron deposition takes place is unclear (7,
8). One possible explanation is that the number of
transferring receptors (TfRs) in the β -cell is higher
than that in the α -cell. It has been suggested that
iron uptake by islet cells in vivo is regulated and
mediated by TfR, and the predominance of TfR ex-
pression in the β -cells of iron-overloaded rats may
result in selective iron deposition in β -cells and pre-
dispose them to damage that leads to diabetes (9).
Kulaksiz et al. (10) recently reported noteworthy
findings with the bioactive peptide hepcidin, which
regulates iron uptake in the intestine. Immunohis-
tochemical and immunoelectron microscopic analy-
ses revealed that hepcidin was exclusively localized
to β -cells and that it was confined to the insulin-
storing secretory granules of the β -cells. This find-
ing suggests that in addition to their known func-
tion in blood glucose regulation, pancreatic β -cells
may be involved in iron metabolism.
In addition to β -cell dysfunction, genetic diabe-
tes and cirrhosis may interfere in diabetic hemo-
chromatosis (6). Iron deposition in muscle can
cause muscle damage, thereby decreasing glucose
uptake by the muscle, and iron accumulation in the
liver may interfere with hepatic insulin extraction,
thereby causing insulin resistance (5). In the cases
of older children with thalassemia treated with long-
term hypertransfusion therapy, insulin resistance
and increased insulin secretion develop before dia-
betes (11). Thus, the development of diabetes in
patients with hemochromatosis may be due to a
combination of insulin deficiency and insulin resis-
tance, and this deficiency may be caused by [1] ex-
haustion of β -cells, [2] iron deposition in the islet
cells, or [3] a combination of both (11).
In conclusion, we performed immunohistochemi-
cal staining of the pancreas of a patient with trans-
fusional iron overload to clarify the relationship be-
tween iron overload and pancreatic β -cell impair-
ment that may result in hyperglycemia. Owing to
the recent advances in early diagnosis and treatment
of hemochromatosis, very few patients present with
hemochromatosis that is serious enough to cause
diabetes. Therefore, we consider that the present
case is quite informative and that our report has
certain significance in understanding the cause and
mechanism of diabetes in patients with hemochro-
matosis.
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